Assetmark, Inc Eagle Pharmaceuticals, Inc. Transaction History

Assetmark, Inc

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	BUY	$41.26 - $51.35 $2,475 - $3,081	60 Added 130.43%	106 $5,000
Q1 2022 May 13, 2022	SELL	$44.58 - $52.6 $133 - $157	-3 Reduced 6.12%	46 $2,000
Q4 2021 Feb 14, 2022	BUY	$45.82 - $56.9 $45 - $56	1 Added 2.08%	49 $2,000
Q2 2021 Aug 16, 2021	BUY	$36.86 - $44.5 $626 - $756	17 Added 54.84%	48 $2,000
Q1 2021 May 14, 2021	BUY	$40.32 - $50.97 $201 - $254	5 Added 19.23%	31 $1,000
Q4 2020 Feb 10, 2021	SELL	$41.72 - $51.34 $834 - $1,026	-20 Reduced 43.48%	26 $1,000
Q3 2020 Nov 13, 2020	SELL	$37.02 - $51.28 $1,554 - $2,153	-42 Reduced 47.73%	46 $2,000
Q2 2020 Aug 11, 2020	SELL	$43.24 - $55.02 $86 - $110	-2 Reduced 2.22%	88 $4,000
Q1 2020 May 12, 2020	SELL	$34.37 - $60.07 $171 - $300	-5 Reduced 5.26%	90 $4,000
Q4 2019 Feb 11, 2020	BUY	$54.32 - $64.31 $271 - $321	5 Added 5.56%	95 $6,000
Q3 2019 Nov 13, 2019	BUY	$53.25 - $59.98 $4,792 - $5,398	90 New	90 $5,000
Q1 2018 May 16, 2018	SELL	$52.16 - $66.86 $104 - $133	-2 Closed	0 $0
Q4 2017 Feb 13, 2018	SELL	$49.6 - $60.87 $2,579 - $3,165	-52 Reduced 96.3%	2 $0
Q3 2017 Nov 08, 2017	BUY	$46.62 - $60.36 $1,585 - $2,052	34 Added 170.0%	54 $3,000
Q2 2017 Aug 15, 2017	BUY	N/A	20	20 $2,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

Stay updated on Assetmark, Inc with notifications on news.